Nintedanib Reddy

Nintedanib, the active ingredient in Nintedanib Reddy, is a tyrosine kinase inhibitor presented as an oral tablet for oral use. It is indicated for the treatment of idiopathic pulmonary fibrosis, systemic sclerosis‑associated interstitial lung disease, and certain forms of non‑small cell lung cancer in adult patients.

GNH USA supplies Nintedanib Reddy as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to meet global demand.

Nintedanib is used in fibrotic lung disorders and selected oncology indications, targeting pathways that drive fibroblast activity and tumor growth. - Idiopathic pulmonary fibrosis: slows disease progression and preserves lung function. - Systemic sclerosis‑associated interstitial lung disease: reduces decline in forced vital capacity. - Non‑small cell lung cancer: used in combination therapy to inhibit tumor angiogenesis and growth.

Nintedanib may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Diarrhea: frequent loose stools, often mild to moderate. - Nausea: feeling of sickness, may be transient. - Vomiting: occasional episodes. - Elevated liver enzymes: increase in ALT/AST values.

Serious or Rare Side Effects: - Hepatotoxicity: severe liver injury, jaundice. - Cardiovascular events: arterial thromboembolism or myocardial infarction. - Severe bleeding: gastrointestinal or intracranial hemorrhage.

When prescribing Nintedanib, clinicians should consider several safety measures and monitoring requirements. - Liver function monitoring: assess ALT, AST, bilirubin before treatment and periodically. - Gastrointestinal management: advise patients to stay hydrated and report severe diarrhea. - Cardiovascular risk assessment: evaluate history of arterial thrombotic events. - Bleeding risk: avoid concomitant anticoagulants unless necessary. - Pregnancy and lactation: safety not established; use only if benefits outweigh risks. - Store at ambient temperature: keep below 25 °C, retain in original container, protect from moisture and light.

Nintedanib can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase plasma levels, risk of toxicity. - Anticoagulants (e.g., warfarin, direct oral anticoagulants): heightened bleeding risk. - P‑glycoprotein inhibitors (e.g., verapamil): may raise exposure.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inducers (e.g., rifampicin): may reduce effectiveness. - Antiplatelet agents (e.g., aspirin, clopidogrel): monitor for bleeding. - NSAIDs: increase gastrointestinal adverse events.